Listed

Rigel Pharmaceuticals Inc

RIGLNasdaqCIK 1034842HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$78.7mRevenue, Q2 FY2026, three months to 2026-06-30$78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 4, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$78.7mRevenue, Q2 FY2026, three months to 2026-06-30$78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure−22.6% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin30.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $23.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure−30.1 pts on a year earlier
  • Net margin22.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $17.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure−36.7 pts on a year earlier
  • Diluted EPS$0.88Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure−73.2% on a year earlier
  • Free cash flownot reported (Capital expenditure not reported)No year-earlier figure to compare

Last eight quarters

Full statements
Revenue$78.7mOperating margin 30.0%
Diluted EPS$0.88, Q2 FY2026
Rigel Pharmaceuticals Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m55.3Revenue, Q3 FY2024, three months to 2024-09-30$55.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure57.6Revenue, Q4 FY2024, three months to 2024-12-31$57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure53.3Revenue, Q1 FY2025, three months to 2025-03-31$53.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure102Revenue, Q2 FY2025, three months to 2025-06-30$101.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure69.5Revenue, Q3 FY2025, three months to 2025-09-30$69.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure69.8Revenue, Q4 FY2025, three months to 2025-12-31$69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure58.8Revenue, Q1 FY2026, three months to 2026-03-31$58.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure78.7Revenue, Q2 FY2026, three months to 2026-06-30$78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%25.4%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $14.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Revenue: $55.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure28.9%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $16.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure23.9%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $12.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Revenue: $53.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure60.1%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $61.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $101.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure40.9%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $28.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Revenue: $69.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure33.2%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $23.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure20.2%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Revenue: $58.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure30.0%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $23.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure
Net margin%22.5%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $12.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Revenue: $55.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure24.9%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $14.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $57.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure21.5%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $11.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $53.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure58.6%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $59.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $101.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure40.2%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $27.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Revenue: $69.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figure384.0%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $268.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Revenue: $69.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015. Derived: 12-month figure less the 9-month figure.Report this figure14.7%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $8.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $58.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure22.0%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $17.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Revenue: $78.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure
Diluted EPS$ per share0.70Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.70 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figurenot reported (Diluted EPS not reported)0.63Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.63 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure3.28Diluted EPS, Q2 FY2025, three months to 2025-06-30$3.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure1.46Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001104659-25-106268.Report this figurenot reported (Diluted EPS not reported)0.44Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-05, accession 0001034842-26-000032.Report this figure0.88Diluted EPS, Q2 FY2026, three months to 2026-06-30$0.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-04, accession 0001034842-26-000052.Report this figure
Free cash flow$mnot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$294.3mOperating margin 42.6%
Diluted EPS$19.48, FY2025
Free cash flow−$74.2m, FY2022
Rigel Pharmaceuticals Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m149Revenue, FY2021, twelve months to 2021-12-31$149.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figure120Revenue, FY2022, twelve months to 2022-12-31$120.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-04, accession 0001558370-25-002169.Report this figure117Revenue, FY2023, twelve months to 2023-12-31$116.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure179Revenue, FY2024, twelve months to 2024-12-31$179.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure294Revenue, FY2025, twelve months to 2025-12-31$294.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(8.4%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$12.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-03-05, accession 0001558370-24-002475.Revenue: $149.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figure(46.2%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$55.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-04, accession 0001558370-25-002169.Revenue: $120.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-04, accession 0001558370-25-002169.Report this figure(17.5%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$20.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $116.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure13.5%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $24.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $179.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure42.6%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $125.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $294.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure
Net margin%(12.0%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$17.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-03-05, accession 0001558370-24-002475.Revenue: $149.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figure(48.7%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$58.6m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-04, accession 0001558370-25-002169.Revenue: $120.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-03-04, accession 0001558370-25-002169.Report this figure(21.5%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$25.1m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $116.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure9.8%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $17.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $179.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure124.7%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $367.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-03, accession 0001034842-26-000015.Revenue: $294.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure
Diluted EPS$ per share(0.11)Diluted EPS, FY2021, twelve months to 2021-12-31−$0.11 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figure(3.44)Diluted EPS, FY2022, twelve months to 2022-12-31−$3.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-03-04, accession 0001558370-25-002169.Report this figure(1.44)Diluted EPS, FY2023, twelve months to 2023-12-31−$1.44 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure0.99Diluted EPS, FY2024, twelve months to 2024-12-31$0.99 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure19.48Diluted EPS, FY2025, twelve months to 2025-12-31$19.48 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-03-03, accession 0001034842-26-000015.Report this figure
Free cash flow$m5.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $5.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-03-05, accession 0001558370-24-002475.Capital expenditure: $627.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figure(74.2)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$73.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-04, accession 0001558370-25-002169.Capital expenditure: $450.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-03-05, accession 0001558370-24-002475.Report this figurenot reported (Capital expenditure not reported)not reported (Capital expenditure not reported)not reported (Capital expenditure not reported)

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Rigel Pharmaceuticals Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$75.9m1,939,818Added+170,911
Soleus Capital Management, L.P.2026-06-30$72.1m1,843,504Added+1,833,504
ARMISTICE CAPITAL, LLC2026-06-30$65.4m1,672,000Added+392,000
STATE STREET CORP2026-06-30$40.7m1,039,994Reduced−80,244
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$30.7m785,107Added+20,914
AMERICAN CENTURY COMPANIES INC2026-06-30$29.0m741,718Added+197,287
D. E. Shaw & Co., Inc.2026-06-30$21.2m542,539Added+96,861
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$18.9m483,175Added+42,549
MARSHALL WACE, LLP2026-06-30$14.4m367,393Reduced−230,985
CM Management, LLC2026-06-30$9.8m250,000Added+15,000

Recent filings

All 940 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Rigel Pharmaceuticals Inc, recent filings
FiledFormWhat it isAccession number
2026-08-0416:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001034842-26-000053
2026-08-0416:06 ET10-QQuarterly reportPeriod 2026-06-300001034842-26-000052
2026-07-0116:11 ET8-K5.02 Departure or appointment of officers or directors0001034842-26-000045
2026-06-1716:05 ET8-K2.01 Completion of an acquisition or disposition0001034842-26-000043
2026-05-2016:10 ET8-K5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results0001034842-26-000041
2026-05-1217:24 ET8-K1.01 Entry into a material agreement0001034842-26-000038
2026-05-0516:08 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001034842-26-000033
2026-05-0516:05 ET10-QQuarterly reportPeriod 2026-03-310001034842-26-000032
2026-04-2116:18 ET8-K1.02 Termination of a material agreement0001034842-26-000027
2026-04-0316:01 ETDEF 14AProxy statementPeriod 2026-05-140001034842-26-000023

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Mar 3, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1034842
Tickers
RIGL
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Accelerated filer
Former names
RIGEL PHARMACEUTICALS INC (to 2026-09-03)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:30 ET. Listed shows no prices and gives no investment advice.